Data Bridge Market Research conducted a recent market intelligence study, thoroughly analysing the Melanoma Therapeutics Market. The newly published report employs an appealing layout that presents essential data using visually engaging tables, graphs, charts, and figures.

The Melanoma Therapeutics report contains top to bottom analysis and estimation of various market related factors that are incredibly crucial for better decision making. Competitive analysis has been carried out in the Melanoma Therapeutics report for the major players in the market, which supports businesses take better moves for enhancing their product and sales. Furthermore, this Melanoma Therapeutics research report takes into consideration several industry verticals such as company profile, contact details of players, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company.

Data Bridge Market Research analyses a growth rate in the melanoma therapeutics market in the forecast period 2023-2030. The expected CAGR of melanoma therapeutics market is tend to be around 16.30% in the mentioned forecast period. The market was valued at USD 3.45 billion in 2022, and it would grow upto USD 11.55 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get a Sample Research Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-melanoma-therapeutics-market

As per the records of WHO, around 132,000 cases of skin cancer occur each year. Furthermore, a 10% decrease in ozone levels is projected to lead to an increase of 4,500 skin cancer cases globally. The incidence of skin allergies, melanoma, and other skin cancers in highly developing countries is high, that serves as an opportunity for drug companies to gain a larger share in these regions. Genes and UV radiations are majorly responsible for causing melanoma.

Key Growth Drivers:

  • Increasing Demand of Radiation Therapy

The radiation therapy is projected to show steady growth during the forecast period due to the growing number of advanced melanoma cases and the increasing use of radiation as an adjuvant therapy post-surgery. Radiation therapy is often used as a primary treatment. It is only administered to stage 4 patients who cannot be treated with surgery.

  • Increase in Skin Cancer

According to records of WHO, about 132,000 cases of skin cancer occur each year. Additionally, a 10% reduction in ozone levels is projected to lead to an increase of 4,500 skin cancer cases worldwide. The incidence of skin allergies, melanoma, and other skin cancers in developing countries is more, that serves as an opportunity for many drug companies to gain a greater share in these regions. This is estimated to increase the demand for these drugs during the forecast period.

The report outlines the involvement of key players, including:

Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Sanofi S.A. (France), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Novartis AG (Switzerland), Genentech, Inc (U.S.), AstraZeneca (U.K.), DAIICHI SANKYO COMPANY, LIMITED (Japan), AB Science (France), AgonOX (U.S.), Eisai Co., Ltd (Japan), Pfizer, Inc.(U.S.)

Key Market Segmentation

Type (Superficial Spreading Melanoma, Nodular Melanoma, Lentigo Maligna Melanoma, Acral Lentiginous Melanoma, Amelanotic Melanoma, Others), Stages (Stage 0, Stage 1, Stage 2, Stage 3, Stage 4, Others), Therapy (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Know More about This Premium Research Report @ https://www.databridgemarketresearch.com/reports/global-melanoma-therapeutics-market

Browse More Reports:

https://www.databridgemarketresearch.com/reports/global-prurigo-nodularis-treatment-market

https://www.databridgemarketresearch.com/reports/global-mens-health-market

https://www.databridgemarketresearch.com/reports/global-in-vitro-diagnostic-ivd-regulatory-affairs-outsourcing-market

https://www.databridgemarketresearch.com/reports/global-adrenocorticotropic-hormone-acth-market

https://www.databridgemarketresearch.com/reports/global-cystic-fibrosis-transmembrane-conductance-regulator-cftr-market

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact Us

US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – 
corporatesales@databridgemarketresearch.com